News
Bevacizumab, Aflibercept Compared for Neovascular AMD
At the end of one year, likelihood of being weaned off treatment was higher for eyes treated with aflibercept versus bevacizumab
At the end of one year, likelihood of being weaned off treatment was higher for eyes treated with aflibercept versus bevacizumab
Outcomes at 2 years comparable among patients with diabetic macular edema receiving aflibercept monotherapy, bevacizumab first
Substantial improvement observed through month 12, which persisted through month 60, but lessened with fewer treatments
Six of 18 indications remain on label for cancer drugs that failed to improve primary end point in trials after receiving accelerated approval